Matches in Wikidata for { <http://www.wikidata.org/entity/Q91896398> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q91896398 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q91896398 description "scientific article published on 01 April 2019" @default.
- Q91896398 description "wetenschappelijk artikel" @default.
- Q91896398 description "наукова стаття, опублікована 1 квітня 2019" @default.
- Q91896398 name "Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial" @default.
- Q91896398 name "Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial" @default.
- Q91896398 type Item @default.
- Q91896398 label "Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial" @default.
- Q91896398 label "Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial" @default.
- Q91896398 prefLabel "Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial" @default.
- Q91896398 prefLabel "Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial" @default.
- Q91896398 P1433 Q91896398-ABCDE361-A788-4861-8541-F700A69F00E5 @default.
- Q91896398 P1476 Q91896398-06E2285F-4DED-412C-9C15-D7AF888974F4 @default.
- Q91896398 P2093 Q91896398-18ABF50C-56B4-42A7-93AC-4CA24A5A0F53 @default.
- Q91896398 P2093 Q91896398-513FE0EE-B8A3-4B5B-AB91-1A9ACED00527 @default.
- Q91896398 P2093 Q91896398-56DC0133-ECE6-4C6A-8A1E-8921DB96C08A @default.
- Q91896398 P2093 Q91896398-56EB1889-157E-49E1-AD9F-126E65FB1966 @default.
- Q91896398 P2093 Q91896398-5E79AE73-911E-47ED-A2D7-5594EB32E336 @default.
- Q91896398 P2093 Q91896398-6980EF66-2D93-463F-80DD-121A8A598AB3 @default.
- Q91896398 P2093 Q91896398-722D03B0-D50B-4C68-80A5-4E5C37E6B2A7 @default.
- Q91896398 P2093 Q91896398-91E190D9-CFC5-4A17-8D26-29521B768AEA @default.
- Q91896398 P2093 Q91896398-C63683DB-B937-4EEC-AB81-A0B518F24D9C @default.
- Q91896398 P2093 Q91896398-D629B2B6-7CB2-484E-A4D2-9BF5174D6ECE @default.
- Q91896398 P2093 Q91896398-F8B39A95-FF0D-41D1-879B-DB65FCD22D65 @default.
- Q91896398 P304 Q91896398-9936ED0C-35F6-4019-A0A8-E852DC45EA49 @default.
- Q91896398 P31 Q91896398-C872CFE8-9B36-49E1-838E-E142880F12D8 @default.
- Q91896398 P356 Q91896398-5AF08D5F-0937-41B4-873D-520C546816CB @default.
- Q91896398 P433 Q91896398-6BDEB6D5-6E62-4B3B-AA56-746FFC4C05C3 @default.
- Q91896398 P478 Q91896398-7546E176-768A-4C9D-BBE6-8D458D438D3D @default.
- Q91896398 P577 Q91896398-947CDC33-68AE-4AE2-A9A7-254594FC8A53 @default.
- Q91896398 P698 Q91896398-F0BC58BA-10BC-4492-865F-8D1CC007BA51 @default.
- Q91896398 P356 J.CLGC.2019.03.017 @default.
- Q91896398 P698 31072748 @default.
- Q91896398 P1433 Q332266 @default.
- Q91896398 P1476 "Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial" @default.
- Q91896398 P2093 "Alessandra Felici" @default.
- Q91896398 P2093 "Aristotelis Bamias" @default.
- Q91896398 P2093 "Avishay Sella" @default.
- Q91896398 P2093 "Bernard Escudier" @default.
- Q91896398 P2093 "Brad Rosbrook" @default.
- Q91896398 P2093 "Jamal Tarazi" @default.
- Q91896398 P2093 "Jochen Casper" @default.
- Q91896398 P2093 "Michael Staehler" @default.
- Q91896398 P2093 "Monica Jardinaud-Lopez" @default.
- Q91896398 P2093 "Sergio Bracarda" @default.
- Q91896398 P2093 "Sylvie Negrier" @default.
- Q91896398 P304 "e689-e703" @default.
- Q91896398 P31 Q13442814 @default.
- Q91896398 P356 "10.1016/J.CLGC.2019.03.017" @default.
- Q91896398 P433 "3" @default.
- Q91896398 P478 "17" @default.
- Q91896398 P577 "2019-04-01T00:00:00Z" @default.
- Q91896398 P698 "31072748" @default.